Radar · Sustainability Tech in Maryland
Best Sustainability Tech Companies in Maryland, United States
The 162 best Sustainability Tech companies in Maryland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novavax.
By Riya SenguptaFinancials
162companies tracked
$5.4Bdisclosed funding
0unicorns
76have raised
FLIAR INTELLIGENCE · SUSTAINABILITY TECH × MARYLAND
Our analysis of 84 Sustainability Tech companies
$19.4b in tracked funding; 85% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
84companies analysed
85%cloud-native stacks
2025funding peak (by rounds)
9unicorns
2016median founding year
173kcombined LinkedIn audience
81%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Sustainability Tech companies in Maryland
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Novavax Developer of novel vaccines for the treatment of infectious diseases 83Product top 14%Patents top 17%Funding top 22%Innovation top 23% All 13 signals ▾Producttop 14% Patentstop 17% Fundingtop 22% Innovationtop 23% Partnerstop 26% Markettop 28% Moattop 29% Fin. healthtop 32% Globaltop 35% Growthtop 37% Newstop 40% Techtop 41% Talentbottom 48% Product: 4 distinct product lines · Company stage: Public Patents: 599 patents matched (strict assignee match) · 193 filings since 2022 vs 135 in 2017-21 rank vs industry peers · Fliar Intelligence Index 83/100 | $2.7B | 33 mo ago | 184 | 1987 | John Jacobs President | 599 patents Patents concentrated in chemistry & materials | 2 launchs · 2 partnerships |
| 2 | Emergent BioSolutions Developer of vaccines primarily for virus infections | $491M | 45 mo ago | 1,600 1,600 → 1,366 (-15%) | 1998 | — | 29 patents Vaccines and therapeutic antibodies targeting high‑risk biothreat pathogens | 1 award |
| 3 | Bioenergy DevCo Provider of anaerobic digestion technology for organic waste and energy solutions | $236M | 39 mo ago | 3 | 2019 | Shawn Kreloff Founder & Board Member | — | — |
| 4 | Precigen Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious… | $234M | 66 mo ago | 25 | 1998 | Thomas Reed Founder | 262 patents Gene and cell therapy platforms, viral vector vaccines, and electroporation delivery technologies. | — |
| 5 | Barinthus Biotherapeutics Developer of T-cell immunotherapeutics to treat multiple diseases | $210M | 29 mo ago | — | 2016 | Adrian Hill Co-Founder | 33 patents Peptide vaccine nanocarriers for cancer immunotherapy and targeted drug delivery | — |
| 6 | Sanaria Developer of whole-parasite malaria vaccines for infectious diseases 48Funding top 23%Patents top 33%Moat top 41%Innovation top 46% All 8 signals ▾Fundingtop 23% Patentstop 33% Moattop 41% Innovationtop 46% Growthtop 47% Marketbottom 44% Techbottom 44% Globalbottom 37% Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $188M | 9 mo ago | 77 | 2003 | — | 134 patents Malaria vaccine production, sporozoite cryopreservation, and vector storage technologies | — |
| 7 | Verdant Microgrid Operator of microgrids to provide electricity to off-grid areas | $150M | 59 mo ago | — | 2019 | Sam Houston Co-Founder | — | — |
| 8 | Current Group Complete solution for smart grid | $113M | 177 mo ago | 21 | 1967 | — | 6 patents Power transformer efficiency monitoring and aquatic flow‑inducing fish guidance technologies | — |
| 9 | adaptive phage therapeutics Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic… | $108M | 36 mo ago | 66 | 2016 | — | — | — |
| 10 | VIRxSYS Developing genetic therapies for HIV and cancer | $106M | 173 mo ago | — | 1998 | Riku Heikki Rautsola Ex President and CEO | 105 patents Therapeutic apoptosis-inducing agents, lentiviral gene‑therapy vectors, and RNA trans‑splicing platforms | — |
| 11 | OpGen Developer of diagnostics and bioinformatics platforms for providers | $78M | 63 mo ago | 100 | 2002 | — | 111 patents Antimicrobial resistance profiling and rapid antibiotic susceptibility testing technologies. | — |
| 12 | Apkudo Offers automated tools for operational planning and analytics for the e-waste industry | $75M | 40 mo ago | 74 | 2011 | Josh Matthews Co-Founder & CEO | 43 patents Patents concentrated in computing, sensing & instrumentation | — |
| 13 | Genvec Developer of gene-based vaccines for hearing loss and balance disorders | $62M | 158 mo ago | 16 | 1992 | — | 331 patents Adenoviral vector platforms for veterinary and human vaccines and gene therapy | — |
| 14 | Iomai Corporation Online dissertation writing help, advice, and resources for graduate students | $54M | 281 mo ago | 110 | 1997 | Gerd Zettlmeissl CEO | 14 patents Patents concentrated in health & consumer products | — |
| 15 | American Gene Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases 55Funding top 24%Patents top 31%Moat top 35%Talent top 35% All 11 signals ▾Fundingtop 24% Patentstop 31% Moattop 35% Talenttop 35% Innovationtop 37% Growthtop 40% Producttop 40% Techtop 46% Marketbottom 36% Globalbottom 36% Newsbottom 22% Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $53M | 7 mo ago | 31 | 2008 | Jeff Galvin Chief Executive Officer | 228 patents Non-integrating viral vectors for gene delivery and HIV immunotherapy, plus gamma‑delta T‑cell activation | — |
| 16 | PharmAthene Developing anthrax vaccine designed to protect against inhalational anthrax. | $50M | 187 mo ago | 15 | 2001 | Vipin Garg CEO | 29 patents Patents concentrated in health & consumer products | — |
| 17 | Maxim Biomedical Diagnostic testing solutions improving public health and healthcare worldwide | $50M | 29 mo ago | 22 22 → 15 (-32%) | 2005 | Joe Ma Founder & President | — | — |
| 18 | Abvacc Developer of vaccines and therapeutics to treat infectious diseases 35Funding top 30%Moat top 38%Patents top 43%Innovation top 50% All 7 signals ▾Fundingtop 30% Moattop 38% Patentstop 43% Innovationtop 50% Talentbottom 49% Marketbottom 37% Globalbottom 31% Funding: Raised $45.5M across 10 rounds · 10 rounds over 3 yrs (3.3/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $46M | 12 mo ago | — | 2023 | M Aman Founder | 6 patents Vaccines targeting bacterial toxins and cell‑wall domains for immunotherapy | — |
| 19 | Blue Pillar Industrial IoT connectivity platform for managing, monitoring, and controlling distributed equipment | $42M | 86 mo ago | 42 | 2006 | — | 17 patents Monitoring, testing, and predictive analytics for emergency power supplies and industrial automation security. | — |
| 20 | Akonni Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification | $40M | 56 mo ago | 12 12 → 15 (+25%) | 2003 | — | — | — |
| 21 | VLP Therapeutics Developer of therapeutic vaccines for the treatment of cancer, infectious and CNS disease | $37M | 34 mo ago | 15 | 2012 | Wataru Akahata Co-Founder & CEO | — | — |
| 22 | Synthetic Biologics Developing oncolytic virus therapies to overcome solid tumor barriers | $31M | 46 mo ago | 21 | 1986 | — | 208 patents Microbiome-protective enzyme therapeutics and engineered biologics for infection and metabolic control | — |
| 23 | Trophogen Protein engineering for potent glycoprotein hormone and growth factor analogs | $31M | 94 mo ago | 6 | 2001 | Bruce Weintraub President | 97 patents Manufacturing long-acting, highly glycosylated therapeutic glycoprotein hormones and analogs. | — |
| 24 | Scanogen Provider of single-molecule biosensors for cancer diagnostics 29Talent top 28%Moat top 32%Funding top 33%Patents top 35% All 9 signals ▾Talenttop 28% Moattop 32% Fundingtop 33% Patentstop 35% Innovationtop 42% Productbottom 44% Globalbottom 35% Techbottom 28% Marketbottom 21% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 4/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $29M | 10 mo ago | 7 | 2011 | — | 26 patents Biosensor and imaging technologies for rapid medical analyte detection and diagnostics | — |
| 25 | Profectus BioSciences Using proprietary discovery engine to develop vaccines against viral infectious diseases and their associated… | $19M | 121 mo ago | 3 | 2005 | — | 41 patents Engineering recombinant viral vectors for gene therapy and vaccine delivery | — |
| 26 | Alphyn Biologics Developer of therapeutics for severe and common skin diseases 27Patents top 28%Moat top 32%Innovation top 33%Funding top 37% All 7 signals ▾Patentstop 28% Moattop 32% Innovationtop 33% Fundingtop 37% Techbottom 43% Globalbottom 40% Marketbottom 16% Patents: 30 patents matched (strict assignee match) · 21 filings since 2022 vs 9 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 30 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $13M | 6 mo ago | 3 | 2019 | — | 25 patents Topical antibacterial skin treatments using croton lechleri-derived pharmaceutical compositions | — |
| 27 | mRNA Developer of therapeutics for the treatment of cancer, rare diseases, and others | $12M | 50 mo ago | 9 | 2016 | Dong Shen CEO | — | — |
| 28 | Dwellwell AI & IoT-driven property maintenance management solutions | $12M | 27 mo ago | 18 | 2018 | Dan Simpkins Founder and CEO | — | 1 award |
| 29 | Functional Genetics Small molecule and antibody therapeutics for viral diseases | $11M | 191 mo ago | 50 | 2000 | — | 90 patents Viral infection inhibition and gene‑perturbation platforms for antibody/therapeutic development | — |
| 30 | Biological Mimetics Innovating biomedical solutions to combat global infections and improve public health | $11M | 24 mo ago | — | 1996 | Peter Nara CEO | 39 patents Inactivated microbial vaccine formulations and multiplex pathogen detection device technologies. | — |
| 31 | PathoVax Prophylactic vaccine against all 15 oncogenic human papillomavirus. | $10M | 73 mo ago | 3 | 2014 | Travis Stiles Co-Founder and Interim CEO | 11 patents Virus-like particle platforms for antigen-specific vaccine and immune response redirection | — |
| 32 | Newport Partners Provider of consulting services for energy efficient green buildings | $9M | 8 mo ago | 9 | 2002 | — | — | — |
| 33 | BioFactura Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs | $8M | 85 mo ago | 33 | 2004 | Darryl Sampey President and CEO | 46 patents Antiviral therapeutics and vaccine compositions for orthopoxvirus infection treatment | — |
| 34 | Zero Point Five Therapeutics Developer of therapeutics for infectious diseases | $7M | 14 mo ago | — | 2018 | Joseph Amprey Co-Founder & CEO | — | — |
| 35 | AccelevirDx Developer of diagnostic assays for HIV | $7M | 14 mo ago | 8 | 2015 | Albine Martin Co-Founder/Investor | — | — |
| 36 | Integrated BioTherapeutics Vaccines and Antibodies for bacterial & viral infections | $5M | 37 mo ago | 43 | 2005 | Javad Aman CEO | 82 patents Therapeutic antibodies and toxin-derived peptides targeting viral and bacterial infections | 1 job opening · 1 launch |
| 37 | Hememics Biotechnologies Developer of techology platform for biopreservation | $5M | 36 mo ago | 13 | 2009 | Stephen Bruttig Chairman | 36 patents Rapid multiplex point‑of‑care biosensors employing carbon‑nanotube nanomaterials | — |
| 38 | Pearl Diagnostics Foundation focused on detection and prevention of fungal infections 13Funding top 35%Talent bottom 49%Global bottom 32%Market bottom 20% All 4 signals ▾Fundingtop 35% Talentbottom 49% Globalbottom 32% Marketbottom 20% Funding: Raised $3.5M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 13/100 | $4M | 3 mo ago | 6 | 2014 | Kieren Marr Founder & CEO | — | — |
| 39 | Astek Diagnostics Manufacturer of blood test diagnostic device | $3M | 26 mo ago | 8 | 2020 | — | — | — |
| 40 | EDAC Labs Electrochemical production company focused on decarbonization | $3M | 34 mo ago | 3 | 2022 | Brian Toll Co-Founder | 3 patents Advanced electrolyzer designs with confined electrolyte for efficient hydrogen production | — |
| 41 | Baltimore Regional Housing Partnership Developer of affordable houses | $3M | 48 mo ago | 39 | 2012 | — | — | 1 job opening |
| 42 | DFH Pharma Developer of pharmaceutical products, focusing on drug development and medical trends | $2M | 8 mo ago | — | 2011 | Carl Wild Founder & CEO | — | — |
| 43 | JumpLights Provider of LED lighting system for horticulture farming | $2M | 13 mo ago | 4 | 2018 | John Peeler CEO | 3 patents Patents concentrated in mechanical & energy engineering | 1 partnership |
| 44 | MF Fire Manufacturer of wood stoves for room heating purposes | $1M | 15 mo ago | 5 | 2014 | Paul Laporte CEO | 24 patents Eco‑friendly wildfire suppression via GPS‑tracked spray systems and chemical firebreaks | — |
| 45 | HBVtech Developer of therapeutics for hepatitis B infection through a single injection | $839K | 9 mo ago | 2 | 2013 | — | 11 patents Therapeutics targeting hepatitis B virus cccDNA elimination and HBsAg reduction | — |
| 46 | ThermoChem Recovery International Technology developer for bioenergy projects | $597K | 13 mo ago | 14 | 1996 | Dan Burciaga President & CEO | 223 patents Carbon feedstock gasification and syngas conditioning for liquid fuel synthesis | — |
| 47 | NeuImmune Developer of vaccine and therapeutics for infectious diseases | $574K | 35 mo ago | — | 2014 | Nathan Lewis Co-Founder | — | — |
| 48 | Pataigin Assays to identify pathogens using mass spectrometry | $555K | 35 mo ago | — | 2014 | Erik Nilsson CEO | 7 patents Biotech sample processing and growth assay analytics for nucleic acid diagnostics. | — |
| 49 | Drizzle Developer of diagnostic kits for the detections & identification of Tuberculosis | $500K | 18 mo ago | 3 | 2018 | — | — | 1 partnership |
| 50 | Whisker Labs Provider of sensor hardware and software infrastructure 55Customers top 18%Growth top 26%Patents top 37%Moat top 38% All 10 signals ▾Customerstop 18% Growthtop 26% Patentstop 37% Moattop 38% Producttop 42% Innovationtop 43% Fundingtop 46% Techtop 50% Globalbottom 40% Marketbottom 37% Customers: Play-Store rating 4.74★ across 7,082 ratings (1 apps) · Review volume +37% in 6 mo Growth: Headcount 26 → 43 (+65%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $250K | 1 mo ago | 43 | 2014 | — | 37 patents Early detection of electrical faults and power quality anomalies in wiring systems | — |
Top 12 Sustainability Tech companies in Maryland
#1
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees$187.8Mraised▾
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees
Developer of whole-parasite malaria vaccines for infectious diseases. The company is developing protective vaccines against malaria and plasmodium falciparum infection in humans.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 23%Patents
top 33%Moat
top 41%Innovation
top 46%Growth
top 47%Market
bottom 44%Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) · Last round Grant (prize money) (Sep 2025)
Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 1/10 · IP moat: 134 patents
Funding rounds
- Sep 2025Grant (prize money)$2M
- Sep 2025Grant (prize money)$5.9M
- Jul 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$988.8K
Investors
NIAID, Gates, HHS
Tech stack
Animate.CssBootstrapContact Form 7Core-JsFont AwesomeGoogle Analytics
#2
Series B · Rockville, Maryland · founded 2008 · 31 employees$52.8Mraised▾
Series B · Rockville, Maryland · founded 2008 · 31 employees
Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases. The company has developed drugs using its delivery platform. The product pipeline includes a liver cancer therapeutic lentivirus and an AIDS therapeutic lentivirus, as well as Parkinson’s disease therapeutic lentivirus, and a familial dysautonomia therapeutic lentivirus.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 24%Patents
top 31%Moat
top 35%Talent
top 35%Innovation
top 37%Growth
top 40%Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) · Last round Series B (Nov 2025)
Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 4/10 · IP moat: 228 patents · 10 curated direct competitors tracked
Funding rounds
- Nov 2025Series B$310K
- Apr 2022Series B$50M
- Nov 2015Series A$1.2M
- Sep 2015Grant (prize money)$232.2K
Founders & team
Investors
NIH, Ride wave ventures, HHS, Gaingels, Alumni Ventures
Tech stack
AddtoanyAddtoany Share ButtonsAmazon SesAmazon Web ServicesBeaver BuilderCdnjs
#3
Series B · Annapolis, Maryland · founded 2019 · 3 employees$12.6Mraised▾
Series B · Annapolis, Maryland · founded 2019 · 3 employees
Developer of therapeutics for severe and common skin diseases. The lead candidate of the company AB-101 is the topical drug to treat skin infections caused by MRSA bacteria, Pseudomonas, and other multi-drug resistant organisms (MDOs). The substance AB-101 is generated by an available tropical plant as its own defense against bacteria.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Patents
top 28%Moat
top 32%Innovation
top 33%Funding
top 37%Tech
bottom 43%Global
bottom 40%Patents: 30 patents matched (strict assignee match) · 21 filings since 2022 vs 9 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 4/10 · IP moat: 30 patents
Innovation: 30 patents (top 42% of patent-holders) · 21 filings since 2022 vs 9 in 2017-21
Audience (LinkedIn): 908 LinkedIn followers
Funding rounds
- Dec 2025Series B$25M
- Mar 2024Series B$5.2M
- May 2023Series A$1.2M
- Sep 2022Series A$3.3M
Investors
Queen City Angels, Angel Physicians Fund, Serial Stage Venture Partners
Tech stack
Animate.CssCloudflareCloudflare Bot ManagementContact Form 7Core-JsGodaddy
#4
Series B · Baltimore, Maryland · founded 2014 · 6 employees$3.5Mraised▾
Series B · Baltimore, Maryland · founded 2014 · 6 employees
Foundation focused on detection and prevention of fungal infections
Fliar Intelligence Index™ 13how this company ranks against its industry peers
Funding
top 35%Talent
bottom 49%Global
bottom 32%Market
bottom 20%Funding: Raised $3.5M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) · Last round Series B (Mar 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Single-market focus (United States)
Funding rounds
- Mar 2026Series B$11.2M
- Jun 2022Series A$3.5M
- Mar 2021Grant (prize money)$976.6K
- Jul 2015Grant (prize money)$175K
Founders & team
Investors
HHS, TEDCO
#5
Funding Raised · Baltimore, Maryland · founded 2011 · 7 employees$28.6Mraised▾
Funding Raised · Baltimore, Maryland · founded 2011 · 7 employees
Provider of single-molecule biosensors for cancer diagnostics. The company's semiconductor-based technology uses DNA supercoiling to convert nucleic acid hybridization into a mechanical signal for rapid diagnostics. The first application is for the detection of drug-resistant microbes, specifically tuberculosis.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Talent
top 28%Moat
top 32%Funding
top 33%Patents
top 35%Innovation
top 42%Product
bottom 44%Talent: Analyst team rating 4/5
Moat: Editorial + unicorn rating 4/10 · IP moat: 26 patents
Funding: Raised $28.6M across 15 rounds · 15 rounds over 13 yrs (1.2/yr) · Last round Grant (prize money) (Jul 2025)
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Jul 2025Grant (prize money)$3M
- Jun 2025Grant (prize money)$5M
- May 2025Grant (prize money)$3.3M
- Aug 2023Grant (prize money)$2M
Investors
HHS
Tech stack
BootstrapApache Http ServerCloudflareJqueryGoogle AnalyticsFont Awesome
#6
Funding Raised · Rockville, Maryland · founded 2023$45.5Mraised▾
Funding Raised · Rockville, Maryland · founded 2023
Developer of vaccines and therapeutics to treat infectious diseases. The company's pipeline includes product candidates for the prevention and treatment of bacterial and viral infections. It has a bacterial program that primarily focuses on staphylococcal infections by targeting a variety of virulence factors such as toxins and critical enzymes produced by S. aureus. The company has also developed a large collection of potently neutralizing fully human and macaque-human chimeric antibody therapeutics and vaccines for filoviruses and the Nipah virus.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 30%Moat
top 38%Patents
top 43%Innovation
top 50%Talent
bottom 49%Market
bottom 37%Funding: Raised $45.5M across 10 rounds · 10 rounds over 3 yrs (3.3/yr) · Last round Grant (prize money) (May 2025)
Moat: Editorial + unicorn rating 4/10 · IP moat: 6 patents
Patents: 6 patents matched (strict assignee match) · 4 filings since 2022 vs 1 in 2017-21 · Latest publication 2025
Funding rounds
- May 2025Grant (prize money)$1.3M
- May 2025Grant (prize money)$1.3M
- Apr 2025Grant (prize money)$6.6M
- Feb 2025Grant (prize money)$3M
Founders & team
Investors
HHS
#7
Funding Raised · Davidsonville, Maryland · founded 2002 · 9 employees$8.8Mraised▾
Funding Raised · Davidsonville, Maryland · founded 2002 · 9 employees
Provider of consulting services for energy efficient green buildings
LinkedIn Pulse recent public activity · Jul 2026
Audience: 396 LinkedIn followers
Funding rounds
- Oct 2025Grant (prize money)$2.6M
- May 2025Grant (prize money)$423K
- May 2025Grant (prize money)$2.6M
- Mar 2025Grant (prize money)$491.1K
Investors
Hud Exchange, OSTI
Tech stack
WixReactGoogle CloudPolyfillLodashPriority Hints
#8
Public · Gaithersburg, Maryland · founded 1987 · 184 employees$2.7Braised▾
Public · Gaithersburg, Maryland · founded 1987 · 184 employees
Developer of novel vaccines for the treatment of infectious diseases. Its pipeline includes a vaccine for respiratory syncytial virus infection, coronavirus, malaria, ebola, and seasonal quadrivalent vaccines for influenza. It uses recombinant nanoparticles and adjuvant technology.
Fliar Intelligence Index™ 83how this company ranks against its industry peers
Product
top 14%Patents
top 17%Funding
top 22%Innovation
top 23%Partners
top 26%Market
top 28%Product: 4 distinct product lines · Company stage: Public
Patents: 599 patents matched (strict assignee match) · 193 filings since 2022 vs 135 in 2017-21 · Latest publication 2026
Funding: Raised $2.7B across 15 rounds · 15 rounds over 21 yrs (0.7/yr) · Last round Post IPO (Sep 2023)
Audience (LinkedIn): 80k LinkedIn followers — 46.1% of this cohort's audience
Activity (LinkedIn): 2 product launches · 2 partnerships (incl. Matrix-M®) announced in 12 mo
Funding rounds
- Sep 2023Post IPO$84.5M
- Jul 2020Grant (prize money)$1.6B
- Jun 2020Post IPO$200M
- Jun 2020Grant (prize money)$60M
Founders & team
Investors
InnovationsKapital, SK bioscience, CEPI, Gates, NIH, PATH
Tech stack
Acquia Cloud PlatformAddtoanyAmazon Web ServicesAosApple Icloud MailBootstrap
#9
Acquired · Germantown, Maryland · founded 2014 · 43 employees$250Kraised▾
Acquired · Germantown, Maryland · founded 2014 · 43 employees
Provider of sensor hardware and software infrastructure. The platform enables energy data to be collected and consumed through its solutions. The solutions are provided for homeowners. It provides home intelligence technologies that detect and alert homeowners to electrical fire hazards across the home.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Customers
top 18%Growth
top 26%Patents
top 37%Moat
top 38%Product
top 42%Innovation
top 43%Customers: Play-Store rating 4.74★ across 7,082 ratings (1 apps) · Review volume +37% in 6 mo
Growth: Headcount 26 → 43 (+65%) across vintages · Fresh capital in last 24 mo
Patents: 37 patents matched (strict assignee match) · 15 filings since 2022 vs 22 in 2017-21 · Latest publication 2026
Funding rounds
- Apr 2026Series C$6.6M
- Nov 2021Series C—
- Dec 2020Conventional Debt$4.7M
- Nov 2019Series B—
Investors
State Farm, Ferguson Ventures, Innovation Incubator, Elemental, Polaris Partners, Co=Creation=Capital
Tech stack
Amazon Web ServicesApple Icloud MailBeaver BuilderCloudflareCloudflare Bot ManagementFont Awesome
#10
Funding Raised · Gaithersburg, Maryland · founded 2011$2.3Mraised▾
Funding Raised · Gaithersburg, Maryland · founded 2011
Developer of pharmaceutical products, focusing on drug development and medical trends. The company strives to improve patient health within the healthcare industry. Its team monitors medical advancements and technology. The company focuses on finding better methods in an evolving industry.
Funding rounds
- Sep 2025Grant (prize money)$986.9K
- Jul 2020Grant (prize money)$943.1K
- Sep 2018Grant (prize money)$171.5K
- Aug 2013Grant (prize money)$186.4K
Founders & team
Investors
HHS
#11
Funding Raised · Baltimore, Maryland · founded 2015 · 8 employees$6.5Mraised▾
Funding Raised · Baltimore, Maryland · founded 2015 · 8 employees
Developer of diagnostic assays for HIV. The assay detects ultra-rare analytes of HIV and other viral infections in the blood. The company uses ddPCR, qPCR, sequencing, and also culture-based methods to develop assays.
Funding rounds
- Apr 2025Grant (prize money)$755.3K
- Feb 2025Grant (prize money)$600K
- Jul 2021Grant (prize money)$600K
- Dec 2019Grant (prize money)$300K
Founders & team
Investors
HHS
Tech stack
Apache Http ServerCloudflare TurnstileCore-JsElementorFancyboxGoogle Analytics
#12
Series A · Baltimore, Maryland · founded 2018$7.2Mraised▾
Series A · Baltimore, Maryland · founded 2018
Developer of therapeutics for infectious diseases. It offers ZP5-9676 a single-dose therapy intended to treat soil-transmitted helminths, including Ascaris (roundworm), Trichuris (whipworm), Necator americanus and the uncommon Ancylostoma duodenale.
Funding rounds
- Apr 2025Series A$4.3M
- Jul 2023Series A$7.2M
Founders & team
Funding & investor landscape
$5.4Btotal disclosed funding
75companies funded
446disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Jeff Galvin
Chief Executive Officer · American Gene
Kieren Marr
Founder & CEO · Pearl Diagnostics
M Aman
Founder · Abvacc
John Jacobs
President · Novavax
Stanley Erck
Advisor to the Board of Directors · Novavax
Carl Wild
Founder & CEO · DFH Pharma
Albine Martin
Co-Founder/Investor · AccelevirDx
Joseph Amprey
Co-Founder & CEO · Zero Point Five Therapeutics
Helen Pentikis
Co-Founder & CEO · Zero Point Five Therapeutics
Adrian Hill
Co-Founder · Barinthus Biotherapeutics
Sarah Gilbert
Co-Founder · Barinthus Biotherapeutics
John Peeler
CEO · JumpLights
Prism market signals · United States · country-scoped Prism corpus, 1,947,485 docs
Market landscape — 10 sub-themes by coverage
Share of Sustainability Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH FROM Maryland · institutions
What Maryland researches in climate adaptation
University of Maryland institutions dominate Maryland's climate-adaptation research, focusing primarily on flood risk and disaster resilience, with a contested, concern-heavy tone (11 concern papers) despite near-neutral mean stance.
22 papersstance +0.0212% breakthrough69% concern
local research themes
Flood Risk Assessment and ManagementDisaster Management and ResilienceTropical and Extratropical Cyclones ResearchClimate change impacts on agricultureClimate Change Communication and PerceptionClimate variability and models
top institutions
- University of Maryland, College Park16
- University of Maryland, Baltimore County2
- University of Maryland Center for Environmental Science1
- Maryland Sea Grant1
- Maryland-National Capital Park and Planning Commission1
Common questions
How many Sustainability Tech companies are there in Maryland, United States?
Radar tracks 162 indexable Sustainability Tech companies headquartered in Maryland, United States that meet our profile-completeness bar.
What is the total funding raised by Sustainability Tech companies in Maryland, United States?
The Sustainability Tech companies in Maryland, United States on this list have raised a combined $5.4B in disclosed equity funding across 75 funded companies.
Which is the highest-funded Sustainability Tech company in Maryland, United States?
Novavax is the highest-funded Sustainability Tech company in Maryland, United States, with $2.7B in disclosed equity funding.
How many Sustainability Tech companies in Maryland, United States are funded?
75 of the 162 Sustainability Tech companies in Maryland, United States on this list have disclosed at least one equity funding round.
How many Sustainability Tech unicorns are there in Maryland, United States?
None of the Sustainability Tech companies in Maryland, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Maryland, United States Sustainability Tech companies?
The most active investors in Maryland, United States Sustainability Tech companies on this list include HHS, Business Innovation Network, TEDCO, OSTI, NIH.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.